Is Vanda Pharmaceuticals An Undervalued Gem?

Photo of author
Written By Dean McHugh

Vanda Pharmaceuticals Inc. is a biopharmaceutical company specializing in treatments for nervous system conditions such as sleep disorders and other unmet medical needs. With a diverse portfolio that includes Hetlioz (tasimelteon), Fanapt (iloperidone), Ponvory (ponesimod), milsaperidone, and tradipitant, VNDA is currently trading below its cash value.

Recent acquisition offers from Future Pak and Cycle Pharmaceuticals highlight its potential, particularly with drugs like Fanapt and milsaperidone. Given its attractive valuation and ongoing bidding war, VNDA is an exciting investment prospect for investors aware of the inherent biotech and M&A headline risks.

Business Overview

Credits: DepositPhotos

Founded in 2003, Vanda Pharmaceuticals develops new therapies for central nervous conditions, sleep disorders, and other unmet medical needs. The company’s commercial products include Hetlioz, Fanapt, and Ponvory.

Hetlioz is FDA-approved for non-24-hour sleep-wake disorder (N24SWD) in adults. It acts as a melatonin receptor agonist, helping regulate sleep-wake cycles. Hetlioz is also in Phase III trials for other sleep disorders and is under regulatory review for jet lag and insomnia.

Fanapt is an antipsychotic approved for schizophrenia and acute bipolar disorder (ATBD) in adults. It works by blocking dopamine D2 and serotonin 5-HT2A receptors. Fanapt is available in oral form and is being developed as a long-acting injectable (LAI), expected to enter Phase III by year-end 2024.

Ponvory is an immune response modifier for relapsing multiple sclerosis (MS). VNDA acquired Ponvory’s US and Canadian rights from Actelion Pharmaceuticals in 2023, and it is exploring additional indications such as psoriasis and ulcerative colitis.

VNDA’s pipeline also includes milsaperidone, an atypical antipsychotic targeting schizophrenia and ATBD, and tradipitant, an NK1 receptor antagonist indicated for gastroparesis, motion sickness, and atopic dermatitis.

Acquisition Offers

VNDA has received acquisition offers from Future Pak and Cycle Pharmaceuticals. Future Pak’s latest offer of $8.50 to $9 per share, including potential contingent value rights (CVR) payments, values VNDA significantly higher than its current share price of $6.24. Cycle Pharmaceuticals’ competing bid is at $8.00 per share.

VNDA’s strategic value lies in its diversified late-stage IP portfolio targeting a sizeable total addressable market (TAM). The company’s robust pipeline and promising drug candidates make it an attractive acquisition target.

Valuation Analysis

VNDA’s market cap is $363.2 million, which is relatively small compared to the valuation implied by the acquisition offers and its aggregate TAM. The company’s balance sheet holds $392.1 million in cash, equivalents, and marketable securities, with no significant debt.

VNDA’s quarterly cash burn is estimated at $115.1 million, implying a cash runway of 3.4 years. However, the company’s recent acquisition of Ponvory’s rights suggests that its cash burn will decrease moving forward. VNDA generated $4.9 million in positive cash flow in Q1 2024, indicating a sustainable financial position.

Investment Caveats and Conclusion

Credits: DepositPhotos

VNDA faces risks related to its stock price speculation and potential FDA setbacks with its late-stage IP. However, its proven drugs and robust financials mitigate these risks.

VNDA’s valuation is compelling even as a standalone company, making it an attractive investment despite potential acquisition rejections.

In summary, VNDA is a promising biotech investment with a diverse late-stage IP portfolio and substantial TAM. Its valuation below cash and ongoing acquisition offers highlight its potential. Despite inherent risks, VNDA’s robust financials and growth prospects make it an attractive proposition for long-term investors.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.